You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

A Clinical Case Symposium: PARP Inhibitors in Advanced Ovarian Cancer and the Impact on Survival

  • Authors: Bradley J. Monk, MD, FACS, FACOG; Nicoletta Colombo, MD, PhD; David O’Malley, MD
  • CME / ABIM MOC Released: 10/20/2022
  • Valid for credit through: 10/20/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, obstetricians/gynecologists (Ob/Gyns), and pathologists.

The goal of this activity is for learners to be better able to determine the most appropriate approaches for caring for patients with advanced OC through a series of real-life cases involving decisions related to PARP inhibitor treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • New and emerging clinical data on PARP inhibitor therapies for advanced OC
  • Have greater competence related to
    • Prescribing the most appropriate, evidence-based regimen for a patient with advanced OC
  • Demonstrate greater confidence in their ability to
    • Incorporate evidenced-based treatment decision-making for patients receiving PARP inhibitor therapies for the treatment of advanced OC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Chair

  • Bradley J. Monk, MD, FACS, FACOG

    Professor, Obstetrics and Gynecology
    Division of Gynecologic Oncology
    University of Arizona College of Medicine
    Director, Principal Investigator, Community Research Development
    HonorHealth Research Institute
    Co-Director GOG-Partners Foundation
    Phoenix, Arizona, United States

     

    Disclosures

    Bradley J. Monk, MD, FACS, FACOG, has the following relevant financial relationships:
    Consultant or advisor for: Acrivon; Adaptimmune Therapeutics; Agenus; Akeso Bio; Amgen; Aravive; AstraZeneca; Bayer; Clovis; Eisai; Elevar; EMD Merck; Genmab/Seagen; GOG Foundation; Gradalis; Heng Rui; ImmunoGen; Karyopharm; Iovance Therapeutics; Laekna Therapeutics; MacroGenics; Merck; Mersana Therapeutics; Myriad; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pieris; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GlaxoSmithKline; US Oncology Research; VBL Therapeutics; Verastem Oncology; Zentalis
    Speaker or member of speakers bureau for: AstraZeneca; Clovis Oncology; Eisai; Merck; Myriad; Roche/Genentech; TESARO/GlaxoSmithKline
    Other: Investigator: Gradalis Inc.; US Oncology Research (Honorarium): Novartis

Faculty

  • Nicoletta Colombo, MD, PhD

    Director
    Program of Gynecologic Oncology
    European Institute of Oncology
    University of Milan – Bicocca
    Milan, Italy

     

    Disclosures

    Nicoletta Colombo, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; Mersana Therapeutics; Merck Sharpe & Dohme/Merck; Novartis; Nuvation Bio; Onxerna; Pfizer; Pieris; Roche
    Research funding from: AstraZeneca; Roche
    Other: Honoraria/Expenses: AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; Mersana Therapeutics; Merck Sharpe & Dohme/Merck; Novartis; Nuvation Bio; Onxerna; Pfizer; Pieris; Roche

  • David O’Malley, MD

    Professor, Department of Obstetrics and Gynecology
    The Ohio State University and Wexner Medical Center
    Director, Division Gynecologic Oncology
    James Comprehensive Cancer Center
    Clinical Trial Advisor (Ovarian Cancer), GOG-Partners Foundation
    Columbus, Ohio, United States

    Disclosures

    David O’Malley, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AdaptImmune; Agenus, Inc; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; Boston Biomedical; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Duality Bio; Eisai; Elevar; Exelixis; Genentech Inc.; Genelux; GlaxoSmithKline; Hoffmann-La Roche Inc.; ImmunoGen, Inc.; Imvax; InterVenn Biosciences; InxMed; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Laekna Therapeutics; Leap Therapeutics, Inc.; Luzsana Biotechology; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics,Inc.; Myriad; Novartis; NovoCure; OncoC4, Inc.; Onconova Therapeutics; Regeneron Pharmaceuticals, Inc.; RepImmune; R-Pharm; Roche Diagnostics; Seagen Inc.; Sorrento Therapeutics; Sutro Biopharma; Tarveda Therapeutics; Toray; Trillium Therapeutics; Umoja Biopharma; Verastem, Inc.; VBL Therapeutics; Vincerx Pharma; Xencor; Zentalis
    Research funding from: AbbVie; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; Bristol Myers Squibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech Inc.; Genmab; GlaxoSmithKline; Hoffmann-La Roche Inc.; ImmunoGen, Inc.; Incyte Corporation; Iovance Biotherapeutics; Karyopharm; LeapTherapeutics, Inc.; Ludwig Institute for Ca; Merck & Co; Merck Sharp & Dohme Corp.; Mersana Therapeutics,Inc.; Novartis; NovoCure; NRG Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc; Precision Therapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc.; RTOG; Rubius Therapeutics; Seagen Inc.; Sutro Biopharma; SWOG; TESARO; Verastem, Inc.

Editor

  • Charlotte Warren

    Senior Director Content Development, Medscape, LLC

    Disclosures

    Charlotte Warren has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and The GOG Foundation, Inc.



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

A Clinical Case Symposium: PARP Inhibitors in Advanced Ovarian Cancer and the Impact on Survival

Authors: Bradley J. Monk, MD, FACS, FACOG; Nicoletta Colombo, MD, PhD; David O’Malley, MDFaculty and Disclosures

CME / ABIM MOC Released: 10/20/2022

Valid for credit through: 10/20/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to determine the most appropriate approaches for caring for patients with advanced OC through a series of real-life cases involving decisions related to PARP inhibitor treatment.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.